Dr. Gerhard Carl Hildebrandt, MD

Dr. Hildebrandt practices at University Hospital (MU Health Care) in Columbia, Missouri.

Dr. Hildebrandt's NPI, 1245568633, was assigned on November 24, 2009. Dr. Hildebrandt graduated from Johannes Gutenberg University of Mainz Faculty of Medicine in 1997. Dr. Hildebrandt holds Missouri license 2022022795.

Dr. Hildebrandt's primary practice is University Hospital (MU Health Care), at 1 Hospital Dr, Columbia, MO 65201 in Boone County. The practice phone is (573) 882-4141.

Dr. Hildebrandt's primary practice is University Hospital (MU Health Care) in Columbia, Missouri. Dr. Hildebrandt is also affiliated with University Hospital. The medical group on file is University of Missouri Health Care. Dmand AI also links Dr. Hildebrandt to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hildebrandt practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hildebrandt's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Hildebrandt's licenses on file in 4 states: Missouri, Kentucky, Louisiana and Utah.

Dmand AI lists breast cancer, chronic leukemia, immune deficiency disease, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Hildebrandt treats.

CMS data shows 545 Medicare services from Dr. Hildebrandt across 7 procedure codes in 2024, for 156 Medicare patients. Medicare paid $27,621 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 156 Medicare patients who saw Dr. Hildebrandt in 2024. The largest group is 65 to 74, with 67 patients. 73% of them have high blood pressure, and 56% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hildebrandt's median patient age at 71, with 53% women.

In 2024, Dr. Hildebrandt wrote 312 Medicare Part D claims for 69 patients. 72% of them were for generic drugs. CMS names the drug for 156 of them, across 7 drugs with 11 or more claims each, at $1,239,419 in total drug cost. In 2023, CMS named 54 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Hildebrandt for performance year 2024, reported as part of a group. Dr. Hildebrandt accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 132 papers to Dr. Hildebrandt, published from 2002 to 2025. 2021 was the busiest year, with 16. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Transplantation, Homologous. Dr. Hildebrandt has published most often in Biol Blood Marrow Transplant. Dr. Hildebrandt's most frequent co-authors are Taiga Nishihori, MD, Amer M. Beitinjaneh, MD and Robert Peter Gale.

Dmand AI links Dr. Hildebrandt to 1 clinical trial. Conditions studied include Anemia, Refractory, with Excess of Blasts and Anemia, Refractory. Open Payments lists research payments to Dr. Hildebrandt that name 1 trial.

CMS Open Payments shows 159 general payments to Dr. Hildebrandt from 32 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. Incyte Corporation paid the most, $24,850. It also lists 3 research payments totaling $93 in 2024, naming 1 clinical trial.

Dr. Hildebrandt graduated from Johannes Gutenberg University of Mainz Faculty of Medicine in 1997.

Dr. Hildebrandt is in network with 12 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.